Sudha S Shankar1, Adrian Vella2, Ralph H Raymond3, Myrlene A Staten4, Roberto A Calle5, Richard N Bergman6, Charlie Cao7, Danny Chen5, Claudio Cobelli8, Chiara Dalla Man8, Mark Deeg1, Jennifer Q Dong5, Douglas S Lee5, David Polidori9, R Paul Robertson10, Hartmut Ruetten11, Darko Stefanovski12, Maria T Vassileva13, Gordon C Weir14, David A Fryburg15. 1. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN. 2. Division of Endocrinology, Diabetes & Metabolism, Mayo Clinic College of Medicine, Rochester, MN. 3. R-Squared Solutions, Skillman, NJ. 4. Kelly Government Solutions for National Institute of Diabetes and Digestive and Kidney Diseases, Rockville, MD. 5. Pfizer, Cambridge, MA, and Groton, CT. 6. Cedars-Sinai Diabetes and Obesity Research Institute, Los Angeles, CA. 7. Takeda Development Center Americas, Deerfield, IL. 8. Department of Information Engineering, University of Padova, Padova, Italy. 9. Janssen Research & Development, San Diego, CA. 10. Pacific Northwest Diabetes Research Institute, Seattle, WA Division of Endocrinology, Departments of Medicine and Pharmacology, University of Washington, Seattle, WA. 11. Sanofi, Paris, France. 12. University of Pennsylvania, Philadelphia, PA. 13. Foundation for the National Institutes of Health, Bethesda, MD. 14. Joslin Diabetes Center, Boston, MA. 15. ROI Biopharma Consulting, East Lyme, CT dfryburg@roibiopharma.com.
Abstract
OBJECTIVE: Standardized, reproducible, and feasible quantification of β-cell function (BCF) is necessary for the evaluation of interventions to improve insulin secretion and important for comparison across studies. We therefore characterized the responses to, and reproducibility of, standardized methods of in vivo BCF across different glucose tolerance states. RESEARCH DESIGN AND METHODS: Participants classified as having normal glucose tolerance (NGT; n = 23), prediabetes (PDM; n = 17), and type 2 diabetes mellitus (T2DM; n = 22) underwent two standardized mixed-meal tolerance tests (MMTT) and two standardized arginine stimulation tests (AST) in a test-retest paradigm and one frequently sampled intravenous glucose tolerance test (FSIGT). RESULTS: From the MMTT, insulin secretion in T2DM was >86% lower compared with NGT or PDM (P < 0.001). Insulin sensitivity (Si) decreased from NGT to PDM (∼50%) to T2DM (93% lower [P < 0.001]). In the AST, insulin secretory response to arginine at basal glucose and during hyperglycemia was lower in T2DM compared with NGT and PDM (>58%; all P < 0.001). FSIGT showed decreases in both insulin secretion and Si across populations (P < 0.001), although Si did not differ significantly between PDM and T2DM populations. Reproducibility was generally good for the MMTT, with intraclass correlation coefficients (ICCs) ranging from ∼0.3 to ∼0.8 depending on population and variable. Reproducibility for the AST was very good, with ICC values >0.8 across all variables and populations. CONCLUSIONS: Standardized MMTT and AST provide reproducible and complementary measures of BCF with characteristics favorable for longitudinal interventional trials use.
OBJECTIVE: Standardized, reproducible, and feasible quantification of β-cell function (BCF) is necessary for the evaluation of interventions to improve insulin secretion and important for comparison across studies. We therefore characterized the responses to, and reproducibility of, standardized methods of in vivo BCF across different glucose tolerance states. RESEARCH DESIGN AND METHODS: Participants classified as having normal glucose tolerance (NGT; n = 23), prediabetes (PDM; n = 17), and type 2 diabetes mellitus (T2DM; n = 22) underwent two standardized mixed-meal tolerance tests (MMTT) and two standardized arginine stimulation tests (AST) in a test-retest paradigm and one frequently sampled intravenous glucose tolerance test (FSIGT). RESULTS: From the MMTT, insulin secretion in T2DM was >86% lower compared with NGT or PDM (P < 0.001). Insulin sensitivity (Si) decreased from NGT to PDM (∼50%) to T2DM (93% lower [P < 0.001]). In the AST, insulin secretory response to arginine at basal glucose and during hyperglycemia was lower in T2DM compared with NGT and PDM (>58%; all P < 0.001). FSIGT showed decreases in both insulin secretion and Si across populations (P < 0.001), although Si did not differ significantly between PDM and T2DM populations. Reproducibility was generally good for the MMTT, with intraclass correlation coefficients (ICCs) ranging from ∼0.3 to ∼0.8 depending on population and variable. Reproducibility for the AST was very good, with ICC values >0.8 across all variables and populations. CONCLUSIONS: Standardized MMTT and AST provide reproducible and complementary measures of BCF with characteristics favorable for longitudinal interventional trials use.
Authors: Giuseppe Derosa; Anna Carbone; Ivano Franzetti; Fabrizio Querci; Elena Fogari; Lucio Bianchi; Aldo Bonaventura; Davide Romano; Arrigo F G Cicero; Pamela Maffioli Journal: Diabetes Res Clin Pract Date: 2012-06-09 Impact factor: 5.602
Authors: N J van der Zijl; G H Goossens; C C M Moors; D H van Raalte; M H A Muskiet; P J W Pouwels; E E Blaak; M Diamant Journal: J Clin Endocrinol Metab Date: 2010-11-17 Impact factor: 5.958
Authors: Marcello C Laurenti; Chiara Dalla Man; Ron T Varghese; James C Andrews; Robert A Rizza; Aleksey Matveyenko; Giuseppe De Nicolao; Claudio Cobelli; Adrian Vella Journal: JCI Insight Date: 2020-04-09
Authors: Tamara S Hannon; Steven E Kahn; Kristina M Utzschneider; Thomas A Buchanan; Kristen J Nadeau; Philip S Zeitler; David A Ehrmann; Silva A Arslanian; Sonia Caprio; Sharon L Edelstein; Peter J Savage; Kieren J Mather Journal: Diabetes Obes Metab Date: 2017-06-22 Impact factor: 6.577
Authors: Hartmut Ruetten; Mathias Gebauer; Ralph H Raymond; Roberto A Calle; Claudio Cobelli; Atalanta Ghosh; R Paul Robertson; Sudha S Shankar; Myrlene A Staten; Darko Stefanovski; Adrian Vella; Kathryn Wright; David A Fryburg Journal: Metab Syndr Relat Disord Date: 2018-08-17 Impact factor: 1.894
Authors: Ron T Varghese; Chiara Dalla Man; Marcello C Laurenti; Francesca Piccinini; Anu Sharma; Meera Shah; Kent R Bailey; Robert A Rizza; Claudio Cobelli; Adrian Vella Journal: Diabetes Obes Metab Date: 2017-09-27 Impact factor: 6.577
Authors: Laura Montefusco; Moufida Ben Nasr; Francesca D'Addio; Cristian Loretelli; Antonio Rossi; Ida Pastore; Giuseppe Daniele; Ahmed Abdelsalam; Anna Maestroni; Marco Dell'Acqua; Elio Ippolito; Emma Assi; Vera Usuelli; Andy Joe Seelam; Roberta Maria Fiorina; Enrica Chebat; Paola Morpurgo; Maria Elena Lunati; Andrea Mario Bolla; Giovanna Finzi; Reza Abdi; Joseph V Bonventre; Stefano Rusconi; Agostino Riva; Domenico Corradi; Pierachille Santus; Manuela Nebuloni; Franco Folli; Gian Vincenzo Zuccotti; Massimo Galli; Paolo Fiorina Journal: Nat Metab Date: 2021-05-25
Authors: Kamal Albarazanji; Andrea R Nawrocki; Bin Gao; Xiaoli Wang; Yixin Jim Wang; Yong-Fu Xiao Journal: Sci Rep Date: 2021-06-04 Impact factor: 4.379